All In Biotech

Drug Trial Radar · NCT03706950

Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART

Multicentre, Open-label, Post-approval Observational Study of Elpida® Used in the First Line Therapy for HIV-1 Infected Patients With the Background of Standard Baseline ART (NNRTI + 2 NRTIs)

Last checked: Nov 19, 2026Latest source record: Oct 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

2,000

Planned (sponsor's estimate)

Start

Mar 15, 2018

Primary completion

Dec 31, 2021

Study completion Dec 31, 2022

Sponsor

Lead sponsor
ViriomIndustry
Sponsor type
Industry
First posted
Oct 16, 2018

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This post-registration observational study is designed to monitor the safety parameters and efficacy of Elpida® in actual practice in the first-line treatment of HIV-1 infected patients on the background of the standard baseline ART.

Conditions

  • HIV-1-infection

Interventions

  • Elpida® + 2 NRTIsDrug

    Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEs and SAEsTime frame: 96 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Regional AIDS Prevention and Control Center

    Astrakhan, Russia · Recruiting

  • Altai Regional Center for the Prevention and Control of AIDS and Infectious Diseases

    Barnaul, Russia · Recruiting

  • Regional Center for the Prevention and Control of AIDS and Infectious Diseases

    Chelyabinsk, Russia · Recruiting

  • Center for AIDS Prevention and Control

    Gorno-Altaysk, Russia · Recruiting

  • Center for the Prevention and Control of AIDS and Infectious Diseases

    Khabarovsk, Russia · Recruiting

  • Clinical Center for AIDS Prevention and Control

    Krasnodar, Russia · Recruiting

  • The State Budgetary Healthcare Institution of Moscow "Infectious Clinical Hospital No. 2 of the Moscow City Health Department" (SGBU ICD No. 2 DZM), Moscow City Center for AIDS Prevention and Control of the Moscow City Health Department

    Moscow, Russia · Recruiting

  • State Regional Clinical Hospital "City Infectious Clinical Hospital No. 1"

    Novosibirsk, Russia · Recruiting

  • Center for AIDS Prevention and Control

    Rostov-on-Don, Russia · Recruiting

  • State Public Health Institution of the Leningrad Region "Center for the Prevention and Control of AIDS and Infectious Diseases"

    Saint Petersburg, Russia · Recruiting

  • St. Petersburg State Budgetary Healthcare Institution "Center for the Prevention and Control of AIDS and Infectious Diseases"

    Saint Petersburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.